Indian pharmaceutical stocks came under heavy selling pressure on Wednesday after US President Donald Trump unveiled a phased tariff plan targeting imported generic medicines. The announcement triggered a sharp decline across the healthcare sector, with investors worried about the long-term impact on Indian drug manufacturers that depend heavily on the US market. The selloff also...
